IMAGE: This table is part of the abstract presented in the press release. view more
Credit: © ELCC 2018
Lugano-Geneva, 12 April 2018 – Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland. (1)
Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, (2) which is the longest follow-up reported to date with anti-programmed death ligand 1 (PD-L1) immunotherapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC). The trial randomised 287 patients from 61 sites across 13 countries with advanced NSCLC to the anti-PD-L1 antibody atezolizumab or docetaxel (chemotherapy).
Overall survival was significantly higher with atezolizumab at two and three years compared with docetaxel. Nearly one-third of patients (32.2%) in the atezolizumab treatment group were alive at two years compared with 16.6% in the docetaxel group. Additionally, at three years, almost twice as many patients (18.7%) were alive in the atezolizumab group compared to the docetaxel group (10.0%). The long-term overall survival benefit with atezolizumab over docetaxel was observed across histology (squamous and non-squamous) and regardless of PD-L1 expression. Even patients with PD-L1 expression in less than 1%
Article originally posted at